Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab

(Mayo Clinic) Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news